--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses.

Masimo reported third-quarter consolidated revenue of $504.6 million, up 5% from the year-ago quarter. Healthcare revenue rose year over year by about 12% to $343.3 million, and non-healthcare ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings ... With an average one-year price target of $167.5, there's a potential 16.14% upside. Analyzing Ratings Among Peers The below ...

Masimo’s flagship product is its Signal Extraction Technology (SET) pulse oximetry ... which included gross margins of 62.5% for healthcare and 35% for non-healthcare. Healthcare gross margins ...

The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...